RECRUITING

Nicotinamide Riboside (NR) to Treat Moyamoya-like Cerebrovascular Disease in Smooth Muscle Dysfunction Syndrome (SMDS)

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to determine whether SMDS patients treated with NR at the proposed dose exhibit decreased glucose uptake in the aorta, to determine if NR treatment results in measurable changes of blood NAD+ and NR levels, to determine if aortic measurements are stable after treatment with NR and to evaluate the safety and tolerability of NR in SMDS patients.

Official Title

Nicotinamide Riboside (NR) to Treat Moyamoya-like Cerebrovascular Disease in Smooth Muscle Dysfunction Syndrome (SMDS)

Quick Facts

Study Start:2024-03-06
Study Completion:2025-07-25
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06280482

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:5 Years to 18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:CHILD, ADULT
Inclusion CriteriaExclusion Criteria
  1. * bodyweight ≥ 12 kg
  2. * native (not surgically replaced) ascending aorta
  3. * diagnosed with SMDS with confirmed ACTA2 mutation disrupting arginine 179
  4. * females with negative urine pregnancy test
  5. * must agree to use acceptable method of contraception, including abstinence, a barrier method (diaphragm or condom), Depo-Provera, or an oral contraceptive, for the duration of the study
  1. * Individuals who have undergone surgery to replace aneurysmal or dissected ascending and root aortic tissue with a graft.
  2. * Additional medical conditions that impair the patient's ability to participate in the study.
  3. * Known allergy or sensitivity to niacin or nicotinamide riboside.
  4. * Prior consumption of niacin or nicotinamide riboside supplement within the prior eight weeks.
  5. * Failure to provide informed consent.
  6. * Inability to tolerate PET/CT imaging and echocardiography without sedation.
  7. * Concurrent participation in another intervention trial.

Contacts and Locations

Study Contact

David R Murdock, MD
CONTACT
(713) 500-6735
David.R.Murdock@uth.tmc.edu
Dianna Milewicz, MD, PhD
CONTACT
(713) 500-6725
Dianna.M.Milewicz@uth.tmc.edu

Principal Investigator

David Murdock, MD
PRINCIPAL_INVESTIGATOR
The University of Texas Health Science Center, Houston

Study Locations (Sites)

The University of Texas Health Science Center at Houston
Houston, Texas, 77030
United States

Collaborators and Investigators

Sponsor: The University of Texas Health Science Center, Houston

  • David Murdock, MD, PRINCIPAL_INVESTIGATOR, The University of Texas Health Science Center, Houston

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-03-06
Study Completion Date2025-07-25

Study Record Updates

Study Start Date2024-03-06
Study Completion Date2025-07-25

Terms related to this study

Keywords Provided by Researchers

  • smooth muscle aortic alpha-actin (ACTA2)
  • arginine 179 residue
  • Nicotinamide Riboside
  • Stroke
  • Cerebrovascular Disease
  • Thoracic Aortic Aneurysms and Dissections

Additional Relevant MeSH Terms

  • Smooth Muscle Dysfunction Syndrome (SMDS)